Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03138759 · ClinicalTrials.gov registry record · Phase 1
Effect of Probenecid on Pexidartinib Pharmacokinetics
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03138759 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 16 participants.
The verdict
NCT03138759, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The primary objective of this trial is to assess the effect of probenecid on the pharmacokinetics (PK) of single-dose pexidartinib in healthy subjects. Secondary objectives are to assess the safety and tolerability of pexidartinib alone and in combination with probenecid. Participants will be confined to the clinic for approximately 32 days. Blood samples will be collected for PK analysis of pexidartinib and metabolites at predose and up to 312 hours (h) post dose.
Interventions
- DRUG Probenecid
- DRUG Pexidartinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-02-27 |
| Est. Completion | 2017-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03138759
The ClinicalTrials.gov registry entry for NCT03138759 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Probenecid is the first listed.
NCT03138759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03138759 about?
NCT03138759 is a clinical study titled "Effect of Probenecid on Pexidartinib Pharmacokinetics". The primary objective of this trial is to assess the effect of probenecid on the pharmacokinetics (PK) of single-dose pexidartinib in healthy subjects. Secondary objectives are to assess the safety and tolerability of pexidartinib alone and in combination with probenecid. Participants will be conf...
What is the current status of trial NCT03138759?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2017-02-27. Estimated completion is 2017-03-30.
What interventions are being tested in trial NCT03138759?
The interventions under investigation include: Probenecid (DRUG), Pexidartinib (DRUG).
Who is sponsoring clinical trial NCT03138759?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.